SPIMACO
2070TASIPharmaBiotech & Life Science
30.74SAR0.98 (3.29%)
- Open
- 29.94
- High
- 31.00
- Low
- 29.82
- Prev. close
- 29.76
- Volume
- 0.17M
- Value
- 5.08M
- Trades
- 816
2070TASIPharmaBiotech & Life Science
(Revenue FY − Revenue FY-1) ÷ |Revenue FY-1|
(Net income FY − Net income FY-1) ÷ |Net income FY-1|
(Revenue FY ÷ Revenue FY-3)^(1/3) − 1; requires positive values
(Revenue FY ÷ Revenue FY-5)^(1/5) − 1; requires positive values
(Net income FY ÷ Net income FY-3)^(1/3) − 1; requires positive values
(Net income FY ÷ Net income FY-5)^(1/5) − 1; requires positive values
(EPS FY ÷ EPS FY-3)^(1/3) − 1; requires reported EPS per year
(EPS FY ÷ EPS FY-5)^(1/5) − 1; requires reported EPS per year
Gross profit FY ÷ Revenue FY
Operating income FY ÷ Revenue FY
Net income FY ÷ Revenue FY
Net income FY ÷ average shareholders’ equity (FY, FY-1); null when closing equity ≤ 0
Net income FY ÷ average total assets (FY, FY-1)
Operating income × (1 − effective tax rate) ÷ (total debt + equity); requires tax data
Price × shares outstanding
Price ÷ EPS (TTM EPS when reported, else net income FY ÷ shares); null when EPS ≤ 0
Price ÷ (shareholders’ equity FY ÷ shares); null when equity ≤ 0
(Market cap + total debt − cash) ÷ EBITDA FY; requires cash and EBITDA
Free cash flow FY ÷ market cap
Dividends per share over the last 12 months (by eligibility date) ÷ price
Dividends per share (12 months) ÷ EPS
Current assets ÷ current liabilities; requires current balances
Total debt FY ÷ shareholders’ equity FY
Total liabilities FY ÷ total assets FY
(Total debt − cash) ÷ EBITDA FY; requires cash and EBITDA
Operating income FY ÷ interest expense FY; requires interest expense
Revenue FY ÷ average total assets (FY, FY-1)
Operating cash flow FY ÷ net income FY; null when net income ≤ 0